Vijaya Diagnostic Q1 FY26 + FY25: Sales Jump 20%, Profit 22%, P/E 72 – South India’s Scan Machine Printing Money Faster Than RBI

1. At a Glance

Vijaya Diagnostic Centre Ltd, the pathology-peddling giant of South India, has once again proven that in India, two things never go out of demand: Bollywood gossip and blood tests. CMP ₹1,052, market cap ₹10,809 Cr, trading at a P/E of 72 — which means investors are paying 72 years’ worth of profit for the privilege of owning a diagnostic lab that still asks patients to “come fasting.” ROE is a healthy 19%, ROCE 21%, and debt-to-equity 0.40 — manageable, like your cholesterol if you avoid biryani twice a week. PAT margin? 20%. Dividend yield? A stingy 0.19% — enough for a packet of glucose biscuits after your sugar test.

2. Introduction

If Apollo and Dr Lal Pathlabs are the Shah Rukh and Salman of Indian diagnostics, Vijaya is that slick South Indian superstar who quietly dubs his movies and suddenly takes pan-India by storm. Born in Hyderabad, they now rule Andhra, dabble in Pune, and are flirting with Kolkata.

Footfalls in Q1 FY25? 0.96 million, tests performed 3.38 million. That’s like testing half of Hyderabad for Vitamin D deficiency in a single quarter. Revenue per footfall jumped to ₹1,621, proving that wellness check-ups are basically disguised shopping sprees for “useless but peace-giving” tests.

And while many diagnostics players whine about pricing pressure, Vijaya runs a hub-and-spoke model that squeezes every last drop from each blood vial — central labs for efficiency, centers for reach, corporate tie-ups for volume. It’s a profit cocktail with 40% operating margins — better than some FMCG companies.

But here’s the kicker: investors are still treating it like it’s the next Infosys, giving it a book value multiple of 13.6×. Lab coat or not, that’s expensive.

3. Business Model – WTF Do They Even Do?

Vijaya makes money by:

• Diagnostics (87%) → Blood, urine, stool (yes, the glamour industries of India), MRI, CT, PET-CT, nuclear medicine. They’ve served 100 million customers to date — basically more than the population of Germany.
• Corporate wellness (13%) → Health check-ups for 400+ MNCs. Translation: forcing IT employees to do annual fasting tests and ECGs while HR sends polite reminders.

Their hub-and-spoke strategy means Hyderabad is the mothership. Tests collected across 146 centers are shipped to 21 reference labs. Hubs make ₹110 Cr per year, spokes ₹25 Cr, and small collection centers ₹2 Cr. It’s like Swiggy, but for your blood samples.

Question for you: when was the last time you got a health package because you wanted to, not because HR threatened your appraisal?

4. Financials Overview

Here’s the Q1 FY26 snapshot (₹ Cr):

Commentary: Unlike some peers stuck with flat growth, Vijaya is compounding like your cholesterol after three biryanis.